IL198852A - Use of an antagonist antibody against vegf in the preparation of a drug for multiple myeloma - Google Patents

Use of an antagonist antibody against vegf in the preparation of a drug for multiple myeloma

Info

Publication number
IL198852A
IL198852A IL198852A IL19885209A IL198852A IL 198852 A IL198852 A IL 198852A IL 198852 A IL198852 A IL 198852A IL 19885209 A IL19885209 A IL 19885209A IL 198852 A IL198852 A IL 198852A
Authority
IL
Israel
Prior art keywords
medicament
manufacture
multiple myeloma
vegf antibody
treating multiple
Prior art date
Application number
IL198852A
Other languages
English (en)
Hebrew (he)
Other versions
IL198852A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL198852A0 publication Critical patent/IL198852A0/en
Publication of IL198852A publication Critical patent/IL198852A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL198852A 2006-12-11 2009-05-20 Use of an antagonist antibody against vegf in the preparation of a drug for multiple myeloma IL198852A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (2)

Publication Number Publication Date
IL198852A0 IL198852A0 (en) 2011-08-01
IL198852A true IL198852A (en) 2013-06-27

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198852A IL198852A (en) 2006-12-11 2009-05-20 Use of an antagonist antibody against vegf in the preparation of a drug for multiple myeloma

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) * 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
CA3001666C (en) 2015-10-12 2021-03-30 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
EE200100184A (et) * 1998-09-25 2002-08-15 Boehringer Ingelheim Pharma Kg Uudsed asendatud indolinoonid inhibeeriva toimegamitmesugustele kinaasidele ja tsükliin/CDK kompleksidele
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
SG177891A1 (en) 2012-02-28
JP2010512407A (ja) 2010-04-22
KR101320198B1 (ko) 2013-10-30
WO2008073509A3 (en) 2009-01-08
MX2009006202A (es) 2009-06-22
CN101547705A (zh) 2009-09-30
DK2099489T3 (da) 2014-08-18
US20100086544A1 (en) 2010-04-08
AU2007333565A1 (en) 2008-06-19
SI2099489T1 (sl) 2014-09-30
RU2482877C2 (ru) 2013-05-27
IL198852A0 (en) 2011-08-01
WO2008073509A2 (en) 2008-06-19
CN101547705B (zh) 2013-06-12
BRPI0717688A2 (pt) 2013-01-22
NZ577058A (en) 2012-04-27
CA2670707A1 (en) 2008-06-19
RU2009126588A (ru) 2011-01-20
KR20090087908A (ko) 2009-08-18
ZA200903489B (en) 2010-08-25
EP2099489B1 (en) 2014-05-21
HK1131064A1 (en) 2010-01-15
EP2099489A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
IL282658A (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
ZA200900545B (en) Antagonist antibody against EPHA2 for the treatment of cancer
PT2152290E (pt) Métodos para administrar anticorpos anti-il-5
IL196919A (en) Use of an anti-cs1 antibody to prepare a drug for combination therapy with lanalidomide in multiple myeloma
IL194776A0 (en) Humanized c-kit antibody
IL240179B (en) Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood
ZA201300949B (en) Humanized anti-factor d antibodies
IL219285A0 (en) A cd20 antibody for use as a medicament for treating multiple sclerosis
IL205547A0 (en) Anti-vegf antibody compounds and methods
IL196806A0 (en) Anti-myostatin antibodies
IL193408A0 (en) Antibody formulation
EP1993539A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL204835A0 (en) Humanized antibody
PT2242773T (pt) Anticorpos monoclonais para o tratamento de tumores
EP2198055A4 (en) HUMANIZED PAI-1 ANTIBODIES
EP1993535A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
SI2094728T1 (sl) Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1993537A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP2186894A4 (en) MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13
EP1996191A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
ZA200903242B (en) Treatment for multiple myeloma
EP1993538A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed